Business
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data CLOVER WaM Major Response Rate for BTKi-Treated Patients 59.0% Company to hold webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercializatio
About this update from Cellectar Biosciences, Inc.
[{"type":"image","alt":"Cellectar Biosciences, Inc.","displaySize":"","headline":null,"caption":"Cellectar Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":296,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/7baccc0d962891d85da2697559b3ccb0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qCQXkIySESVHpCuJXj8EOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7baccc0d962891d85da2697559b3ccb0","width":296,"height":300}},"lazy":false},{"type":"text","content":"Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data","length":168,"tagName":"p"},{"type":"text","content":"CLOVER WaM Major Response Rate for BTKi-Treated Patients 59.0%","length":62,"tagName":"p"},{"type":"text","content":"Company to hold webcast and conference call at 8:30 AM ET today","length":63,"tagName":"p"},{"type":"text","content":"FLORHAM PARK, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended March 31, 2025, and provided a corporate update on its promising portfolio of clinical and pre-clinical radiopharmaceutical therapeutics.","length":437,"tagName":"p"},{"type":"text","content":"“Notwithstanding the need to gather additional clinical data for iopofosine I 131, as previously announced, we believe that the Phase 2 CLOVER WaM clinical trial data for this product candidate are impressive. We plan to present these data to the EMA during the second quarter of 2025 as part of the registration package seeking conditional marketing approval. We anticipate a response regarding the regulatory pathway from the European agency before the end of the third quarter of this year,” said James Caruso, president and CEO of Cellectar. “In addition to iopofosine I 131, we have developed a pipeline of radiotherapeutic candidates, including our alpha- and Auger-emitting radioconjugates, with observed preclinical activity in solid tumor models. With cash into the fourth quarter of this year we are evaluating a variety of funding pathways to successfully advan...